Developing vaccines for immunocompromised individuals presents unique challenges due to their reduced ability to mount strong immune responses. Conditions such as HIV, cancer, and post-transplant therapies often lead to immune suppression, making standard vaccination protocols less effective. Tailored strategies are essential—these may include altered dosing regimens, booster schedules, or the use of non-replicating platforms to enhance safety and efficacy. Instead of live-attenuated vaccines, which may pose risks, inactivated or subunit-based options are generally preferred. Advances in immunodiagnostics are also contributing to better patient-specific planning, allowing for closer monitoring of response and refinement of vaccine timing. As global health initiatives strive for inclusive protection, designing reliable immunization pathways for immunocompromised individuals remains crucial to safeguarding this high-risk population and minimizing preventable disease burdens.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States